227 related articles for article (PubMed ID: 18086757)
1. Menopausal hormone therapy and risk of epithelial ovarian cancer.
Rossing MA; Cushing-Haugen KL; Wicklund KG; Doherty JA; Weiss NS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2548-56. PubMed ID: 18086757
[TBL] [Abstract][Full Text] [Related]
2. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
3. Menopausal hormones and risk of ovarian cancer.
Moorman PG; Schildkraut JM; Calingaert B; Halabi S; Berchuck A
Am J Obstet Gynecol; 2005 Jul; 193(1):76-82. PubMed ID: 16021062
[TBL] [Abstract][Full Text] [Related]
4. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort.
Wang SM; Pfeiffer RM; Gierach GL; Falk RT
Breast Cancer Res; 2020 Nov; 22(1):129. PubMed ID: 33239054
[TBL] [Abstract][Full Text] [Related]
5. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.
Pearce CL; Chung K; Pike MC; Wu AH
Cancer; 2009 Feb; 115(3):531-9. PubMed ID: 19127543
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of postmenopausal hormone use and ovarian cancer risk.
Danforth KN; Tworoger SS; Hecht JL; Rosner BA; Colditz GA; Hankinson SE
Br J Cancer; 2007 Jan; 96(1):151-6. PubMed ID: 17179984
[TBL] [Abstract][Full Text] [Related]
9. Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?
Dieli-Conwright CM; Sullivan-Halley J; Patel A; Press M; Malone K; Ursin G; Burkman R; Strom B; Simon M; Weiss L; Marchbanks P; Folger S; Spirtas R; Deapen D; Bernstein L
Cancer Causes Control; 2011 Mar; 22(3):515-22. PubMed ID: 21213036
[TBL] [Abstract][Full Text] [Related]
10. Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH-AARP Diet and Health Study Cohort.
Brinton LA; Schwartz L; Spitz MR; Park Y; Hollenbeck AR; Gierach GL
Cancer Causes Control; 2012 Mar; 23(3):487-96. PubMed ID: 22367699
[TBL] [Abstract][Full Text] [Related]
11. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.
Trabert B; Wentzensen N; Yang HP; Sherman ME; Hollenbeck A; Danforth KN; Park Y; Brinton LA
Br J Cancer; 2012 Sep; 107(7):1181-7. PubMed ID: 22929888
[TBL] [Abstract][Full Text] [Related]
12. Long-term postmenopausal hormone therapy and endometrial cancer.
Razavi P; Pike MC; Horn-Ross PL; Templeman C; Bernstein L; Ursin G
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):475-83. PubMed ID: 20086105
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
14. Sexual activity and vaginal symptoms in the postintervention phase of the Women's Health Initiative Hormone Therapy Trials.
Gass M; Larson J; Cochrane B; Manson JE; Lane D; Barnabei V; Ockene J; Stefanick ML; Mouton C
Menopause; 2018 Mar; 25(3):252-264. PubMed ID: 29112594
[TBL] [Abstract][Full Text] [Related]
15. Association between contemporary hormonal contraception and ovarian cancer in women of reproductive age in Denmark: prospective, nationwide cohort study.
Iversen L; Fielding S; Lidegaard Ø; Mørch LS; Skovlund CW; Hannaford PC
BMJ; 2018 Sep; 362():k3609. PubMed ID: 30257920
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy and risk of epithelial ovarian cancer.
Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
[TBL] [Abstract][Full Text] [Related]
17. Menopausal hormone therapy treatment options and ovarian cancer risk: A Swedish prospective population-based matched-cohort study.
Simin J; Tamimi RM; Callens S; Engstrand L; Brusselaers N
Int J Cancer; 2020 Jul; 147(1):33-44. PubMed ID: 31584190
[TBL] [Abstract][Full Text] [Related]
18. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
19. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
Botteri E; Støer NC; Sakshaug S; Graff-Iversen S; Vangen S; Hofvind S; Ursin G; Weiderpass E
Int J Cancer; 2017 Nov; 141(9):1763-1770. PubMed ID: 28685818
[TBL] [Abstract][Full Text] [Related]
20. Menopausal hormone therapy and mortality among endometrial cancer patients in the NIH-AARP Diet and Health Study.
Felix AS; Arem H; Trabert B; Gierach GL; Park Y; Pfeiffer RM; Brinton LA
Cancer Causes Control; 2015 Aug; 26(8):1055-63. PubMed ID: 25962764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
